ADHD-Focused Cingulate Prices Public Offering, Shares Detailed Pivotal Trial Data
Portfolio Pulse from Vandana Singh
Cingulate Inc (NASDAQ: CING) has priced its $4-million public offering at around 58 cents per share, which includes 6.93 million shares and Series A and Series B warrants. The company also announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for ADHD. The data did not achieve statistical significance on the primary efficacy endpoint but showed a trend toward significance in improving PERMP scores. Cingulate shares were down 5.14% at 55 cents midday Monday.
September 11, 2023 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cingulate Inc's stock price fell after the company priced its public offering and announced Phase 3 trial results for its ADHD drug, CTx-1301. The trial data did not meet the primary efficacy endpoint, but showed a trend toward significance.
The company's stock price fell after the announcement of the public offering and the Phase 3 trial results. The trial data did not meet the primary efficacy endpoint, which could have negatively impacted investor sentiment. However, the data showed a trend toward significance, which could potentially mitigate the negative impact in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100